<DOC>
	<DOCNO>NCT01946880</DOCNO>
	<brief_summary>This trial seek describe effect withdrawal mycophenolate mofetil ( MMF ) risk clinically significant disease reactivation quiescent SLE patient long-term MMF therapy .</brief_summary>
	<brief_title>Randomized MMF Withdrawal Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>Participants inactive disease least 24 week enrol . Half subject continue MMF half subject taper MMF within 12 week . All subject continue hydroxychloroquine small dos prednisone need . Subject visit ass endpoint occur every 4 week Day 0 Week 24 Weeks 32 , 40 , 48 , 60 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Able willing give write informed consent comply requirement study ; 2 . Age 18 70 year , inclusive , randomization ; 3 . Diagnosis SLE , per American College Rheumatology ( ACR ) criteria ; 4. mSLEDAI score &lt; 4 screen visit ( SLEDAI score without serology ) ; 5 . Physician Global Assessment ( 03 ) score 1 less screening visit ; 6 . On stable dose MMF ( 10003000 mg/day ) least 12 week prior randomization ; 7 . Total duration stable decrease MMF therapy must least : two year subject initiate MMF renal indication ( without concurrent extrarenal manifestation ) , one year subject initiate MMF extrarenal indication . 8 . If subject prednisone corticosteroid , follow criterion must meet : dose may exceed 10 mg/day ( equivalent ) 12 week prior randomization ; however , temporary ( 4 total day ) increase , exceed 20mg/day , permit ; dose must hold stable four week prior randomization ( temporary increase within 4 week randomization permit ) . 9 . If subject history B cell deplete therapy within past 3 year , presence CD19 positive cell must document within 12 week prior screen ; 10 . On maintenance HCQ chloroquine stable dose least 12 week prior randomization . 1 . A history lifethreatening neuropsychiatric SLE within 1 calendar year prior randomization ; 2 . Any following laboratory abnormality screen visit : Proteinuria define spot protein/creatinine ratio &gt; 1.0 mg/mg ; Serum creatinine &gt; 2.0 mg/dL ; Transaminases &gt; 2.5x upper limit normal ( ULN ) ; Hemoglobin &lt; 9 g/dL , unless subject document hemoglobinopathy ; White blood count ( WBC ) &lt; 2000/mm^3 ( equivalent &lt; 2 x10^9/L ) ; Neutrophils &lt; 1000/mm^3 ( equivalent &lt; 1 x10^9/L ) ; Platelet count &lt; 75,000/mm^3 ( equivalent &lt; 75 x 10^9/L ) . 3 . Prednisone &gt; 25 mg/day ( equivalent ) within 24 week prior randomization lupus activity ; 4 . Concomitant immunosuppressant include limited azathioprine , methotrexate , 6mercaptopurine , leflunomide , calcineurin inhibitor , antitumor necrosis factor agent within 12 week prior randomization ; 5 . Plasmapheresis IV immunoglobulin within 12 week prior randomization ; 6 . Cyclophosphamide therapy within 24 week prior randomization ; 7 . Concomitant therapy belimumab within 24 week prior randomization ; 8 . B cell deplete therapy within two calendar year randomization ; 9 . Experimental therapy within 24 week , five halflives agent , whichever longer , prior randomization ; 10 . Solid organ stem cell transplantation ; 11 . Identified definitive diagnosis another autoimmune disease may require immunosuppression treatment , include limited : rheumatoid arthritis , scleroderma , primary Sjogren 's syndrome , primary vasculitis , psoriasis , multiple sclerosis , ankylose spondylitis , inflammatory bowel disease . 12 . Chronic infection include , limited , human immunodeficiency virus ( HIV ) , active tuberculosis ( TB ) , currently receive therapy ) ) , hepatitis B hepatitis C , latent systemic fungal infection ; 13 . At within 12 week screen : history current positive purify protein derivative ( PPD ) ( &gt; 5 mm induration regardless prior Bacillus CalmetteGuérin ( BCG ) vaccine administration ) positive QuantiFERON unless documentation exist completion least one month prophylaxis latent TB complete treatment active TB ; indeterminate QuantiFERON® unless follow subsequent negative PPD negative QuantiFERON . 14 . History malignancy within last five year , except resect basal squamous cell carcinoma , treat cervical dysplasia , treat situ cervical cancer Grade I ; 15 . Pregnant lactating , intention pursue pregnancy within three month completion study ; 16 . Unable unwilling use reliable method contraception , outline Mycophenolate REMS ( e.g. , Risk Evaluation Mitigation Strategy ) , four week prior randomization 6 week completion study . This criterion apply female reproductive potential . ( Reference : Mycophenolate REMS , Program Resources Educational Materials , Information Patients , What birth control option ? Access link : ( http : //www.mycophenolaterems.com/PatientOverview.aspx ) . 17 . Drug alcohol abuse within one calendar year randomization ; 18 . Other medical psychiatric condition investigator feel would place subject special risk participation protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Mycophenolate Mofetil ( MMF )</keyword>
</DOC>